We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00767650
Recruitment Status : Completed
First Posted : October 7, 2008
Last Update Posted : July 2, 2017
Information provided by:

Study Description
Brief Summary:

This study will use neuropsychological tests to look at nervous system side effects of Cyclosporine (CsA) in patients with aplastic anemia. CsA is used as part of an immunosuppressive regimen in treating severe aplastic anemia. The drug can produce nervous system side effects, such as tremor and, less commonly, insomnia, anxiety, headache, confusion or seizures. This study will look at effects of CsA on intellectual ability, depression, anxiety, attention, concentration, memory, perception, coordination, and thought processing in patients

Patients 15 years of age or older who have severe aplastic anemia may be eligible for this study if they:

  • are co-enrolled in a Clinical Center protocol in which they will receive CsA
  • have not taken CsA for 6 months before enrolling in this study

Participants undergo neuropsychological testing. In addition, they provide blood samples and their clinical data are reviewed for things that may influence the interpretation of findings from the testing, such as results of blood tests, types of medications taken, number of transfusions required, etc. The procedures are as follows:

Before first dose of cyclosporine:

  • Patients are asked about prior problems with their nervous system, prior treatment for their aplastic anemia (including transfusions), prior infections, and current medications. They then complete the following sets of tests:
  • Battery 1: A set of three tests that measure intellectual ability, level of depression (if any) and level of anxiety (if any).
  • Battery 2: A set of seven tests that measure changes in the central nervous system and how these changes affect attention, concentration, memory, perception, coordination, and thought processing.
  • Patients provide a half teaspoon of blood for this study at the same time blood is collected for their primary treatment protocol.

    6 months and 12 months after starting cyclosporine

  • Patients are asked about treatment for their aplastic anemia (including transfusions), infections, and changes in medications that have occurred since they started taking cyclosporine. They then repeat the set of tests in Battery 2.
  • Patients provide a half teaspoon of blood for this study at the same time blood is collected for their primary treatment protocol.

Condition or disease
Aplastic Anemia

Detailed Description:

Cyclosporine (CsA) is widely used in the treatment of aplastic anemia as well as to provide immunosuppression after transplantation. CsA has a spectrum of neurologic and more subtle, poorly investigated neuropsychological functional effects. In the NHLBI, a unique opportunity exists to evaluate changes in neuropsychological function following CsA in a large cohort of aplastic anemia patients accrued to NHLBI treatment protocols.

With increased success in treating blood diseases with immunosuppressive therapy or stem cell transplantation that utilize CsA in the treatment regimen, patients are enjoying prolonged survival during which quality of life becomes an increasingly relevant concern. We therefore propose this natural history protocol designed to evaluate neuropsychological functioning before, during, and after CsA administration in severe aplastic anemia patients.

The primary objective is to evaluate changes in attention, language, memory, spatial/motor and executive function domains following CsA therapy using well established neuropsychological tests including the Neuropsychological Assessment Battery (NAB) Screening Module, Revised Hopkins Verbal Learning Test, Revised Brief Visual-spatial Memory Test, Judgment of Line Orientation test, Grooved Pegboard, Trail Making Test and the two performance subsets in Wechsler Adult Intelligence Scale-III. IQ test by Wechsler Abbreviated Scale of Intelligence and depression/anxiety level will be screened once prior to formal testing. Measures will also be correlated with clinical status, standard CsA side effects, CsA drug levels and relevant biochemical lab values at each time point to control the testing accuracy and explore potential correlation.

Study Design

Study Type : Observational
Actual Enrollment : 7 participants
Time Perspective: Prospective
Official Title: Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia
Study Start Date : September 23, 2008
Estimated Study Completion Date : June 28, 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   15 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Diagnosed with aplastic anemia.
  • Co-enrolled on a Clinical Center CsA treatment protocol that prescribes CsA (included but not limited to initial treatment cohort in both rabbit and horse ATG arm for the aplastic anemia patients).
  • Age greater than or equal to 15 years old.


  • Prior use of cyclosporine within 6 months to next line of treatment.
  • History of learning disability (i.e. dyslexia).
  • Unable to read and speak English (the neuropsychological testing tools are validated for use in English speaking subjects only).
  • Life expectancy less than six months or when clinical status prevents full performance with testing.
  • Either adult patients or guardians for the minor patient, unable to comprehend the investigational nature of the study and provide informed consent.
  • Inability or unwillingness to come to Clinical Center for the 6-month and 12-month follow-up appointments.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00767650

United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
More Information

ClinicalTrials.gov Identifier: NCT00767650     History of Changes
Other Study ID Numbers: 080222
First Posted: October 7, 2008    Key Record Dates
Last Update Posted: July 2, 2017
Last Verified: June 28, 2011

Keywords provided by National Institutes of Health Clinical Center (CC):
Aplastic Anemia
Neurophyschological Side Effect

Additional relevant MeSH terms:
Anemia, Aplastic
Hematologic Diseases
Bone Marrow Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs